Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals financial constraints with limited cash reserves and working capital, increased G&A expenses, and decreased R&D spending. While management is optimistic about product launches and partnerships, the market entry challenges, competitive pressures, and supply chain risks pose significant uncertainties. The Q&A section highlights the company's strategic focus but also underscores financial limitations and the need for careful execution. Overall, the negative financial health and strategic risks outweigh positive developments, leading to a negative sentiment rating.
Key Financial Performance
Cash and Cash Equivalents $23 million as of September 30, 2025, with a working capital of approximately $3.8 million. This was supported by $18.7 million in net proceeds from sales of common stock and $7.3 million in grant payments during the quarter.
General and Administrative (G&A) Expenses $2.5 million in Q3 2025, compared to $2 million in Q3 2024, reflecting a 25% increase. The increase was primarily due to higher professional services and commercial readiness expenses driven by the expanded business strategy.
Research and Development (R&D) Expenses $1.2 million in Q3 2025, compared to $2.7 million in Q3 2024, reflecting a 56% decrease. The decrease was due to an increase in contra R&D expenses from nondilutive funding, reduced manufacturing costs for Ovaprene, and lower personnel costs, partially offset by increased costs for other clinical and preclinical programs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DARE to PLAY Sildenafil Cream: The company is on track to launch this product through a 503B outsourcing facility by the end of 2025. It is a topical Sildenafil formulation designed specifically for women, supported by clinical data demonstrating increased genital blood flow and arousal sensation. The product will be available in all 50 states by early 2026.
DARE to RESTORE vaginal probiotic products: Two proprietary vaginal probiotic products are planned for launch in Q1 2026. These products aim to support the vaginal microbiome and will not require a prescription.
DARE to RECLAIM intravaginal ring: A combination estradiol and progesterone intravaginal ring targeting perimenopause and menopause is planned for early 2027. It will be available via 503B compounding and potentially through FDA approval.
Women's sexual health market: DARE to PLAY Sildenafil Cream is positioned as the first meaningful prescription innovation in the female sexual wellness category, targeting a large under-recognized market.
Compounded hormone therapy market: DARE to RECLAIM targets the $4.5 billion compounded hormone therapy market, offering a unique non-oral monthly form of estradiol and progesterone.
Dual path strategy: The company is commercializing proprietary formulations through 503B compounding while pursuing FDA approval and advancing select solutions as branded consumer health products.
Grant funding: Programs like Ovaprene, DARE-HPV, and DARE-LARC1 are supported by nondilutive funding from organizations like NIH, ARPA-H, and the Gates Foundation.
Collaborative approach: Daré collaborates with academic innovators, small companies, and public funding sources to accelerate the development and commercialization of women's health solutions.
Balanced strategy: The company integrates short-term commercial execution with long-term R&D investment to reduce reliance on dilutive capital and build a sustainable financial model.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company is pursuing FDA approval for several products, including DARE to PLAY Sildenafil Cream and DARE to RECLAIM. Regulatory approval processes are complex and time-consuming, and delays or failures could impact product launches and revenue generation.
Market Entry Challenges: The company plans to launch DARE to PLAY Sildenafil Cream through a 503B outsourcing facility, which involves navigating both federal and state-specific requirements. Delays in meeting these requirements could hinder timely market entry.
Financial Constraints: The company has limited cash reserves ($23 million) and working capital ($3.8 million). While it has received grant funding and proceeds from stock sales, financial constraints could limit its ability to execute its dual path strategy effectively.
Competitive Pressures: The company is entering markets with significant unmet needs but may face competition from existing and future products. Establishing a foothold in these markets will require significant marketing and educational efforts.
Supply Chain Risks: The company relies on partnerships with 503B outsourcing facilities and other third parties for manufacturing and distribution. Any disruptions in these partnerships could impact product availability.
Strategic Execution Risks: The dual path strategy of pursuing both FDA approval and 503B compounding for products like DARE to PLAY Sildenafil Cream and DARE to RECLAIM requires careful coordination. Missteps could delay product launches or dilute focus.
Economic Uncertainties: Broader economic conditions could impact consumer spending on non-essential health products, affecting the adoption of products like DARE to PLAY Sildenafil Cream and DARE to RESTORE.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercial availability of DARE to PLAY Sildenafil Cream: Daré remains on track to support the commercial availability of DARE to PLAY Sildenafil Cream through a 503B outsourcing facility before the end of 2025. Prescriptions are expected to be fulfilled in select states in December 2025 and in all 50 states by early 2026.
Introduction of DARE to RESTORE product line: Daré plans to launch two DARE to RESTORE vaginal probiotic products in the U.S. in the first quarter of 2026. These products are designed to support the vaginal microbiome and will not require a physician's prescription.
Launch of DARE to RECLAIM intravaginal ring: Daré is targeting early 2027 for the availability of DARE to RECLAIM, a combination estradiol and progesterone intravaginal ring for women experiencing perimenopause and menopause. The product will be pursued through both FDA approval and 503B compounding pathways.
Ovaprene Phase III clinical study: Enrollment in the pivotal Phase III clinical study of Ovaprene, a non-hormonal contraceptive, is ongoing and expected to be completed in 2026. Final analysis of study endpoints, including pregnancy rate, will follow.
DARE-HPV development: DARE-HPV, an intravaginal therapy for persistent high-risk human papillomavirus infection, is advancing with funding from ARPA-H and NIH grants.
DARE-LARC1 preclinical development: DARE-LARC1, a long-acting contraceptive with remote pause-resume control, is in preclinical development with recent grant funding received to support its progress.
DARE NHC preclinical research: DARE NHC, a nonhormonal intravaginal contraceptive for low and middle-income countries, is in preclinical research with anticipated grant funding to support its development.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are your thoughts on the FDA's recent reversal and guidance on hormone replacement therapy and menopause? What feedback have you received since the decision, and how can you fill the treatment gap in the near term?
A:Sabrina Johnson expressed enthusiasm about the FDA's decision, highlighting the company's development of the DARE to RECLAIM hormone therapy vaginal ring. She noted the product's alignment with the Menopause Society's recommendations and its potential benefits for bone, brain, and cardiovascular health. She also mentioned positive feedback from healthcare providers and the potential for the product to address the treatment gap.
Q:Will the DARE to RECLAIM product be available through a compounder or via FDA approval?
A:Sabrina Johnson stated that both options are being pursued. The company is working with a third-party 503B outsourcing facility to manufacture the product while continuing the FDA approval process. The FDA has aligned that only one Phase III trial is required, and the company is working on finalizing the trial design and requirements.
Q:How are you prioritizing R&D programs now that you have a decent cash runway?
A:Sabrina Johnson explained that the company is focusing on advancing programs like DARE to PLAY Sildenafil Cream, DARE to RECLAIM, and DARE to RESTORE. They are prioritizing grant-funded programs such as Ovaprene and DARE-HPV, which are in later stages of development. The company is also focusing on opportunities with a clear regulatory roadmap and market potential.
Q:What other partnerships are you considering to increase awareness for DARE to PLAY, given the partnership with Rosy Wellness?
A:Sabrina Johnson outlined a multi-pronged approach, including clinician awareness through conferences and webinars, an online health portal via Medvantx for easy prescription access, and online advertising through platforms like Facebook, Instagram, and podcasts. She mentioned plans for additional partnerships once the product is available nationwide.
Q:Is there additional capacity left on the ATM?
A:Sabrina Johnson explained that the company is subject to baby shelf limitations due to its market cap, which restricts the use of the ATM at this time.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were detailed and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARPA
Bioscience
Cream outsourcing
Cream prescription
Dr
FDA endpoint
Health Network
Institute Women
LARC
MarDee
Milken Institute
RD
Section
Women Health
blood flow
clinician
collaboration
completion
dot
engagement
estradiol
formulation woman
gap woman
grant funding
increase
installment
introduction
model
partner
payment
prescription state
product woman
requirement
royalty
science world
solution woman
website
woman Cream
world solution
DARE Transcript
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call indicates a mixed outlook. The 25% revenue growth is positive, but the net loss and increased R&D expenses raise concerns. The dual path strategy offers potential but carries regulatory and execution risks. No new partnerships or changes in guidance were mentioned, and shareholder return plans were not discussed. Without information on market cap, a neutral sentiment is appropriate, reflecting balanced positive and negative factors.
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Unknown3-26
The company's reliance on non-dilutive funding and limited working capital pose sustainability concerns. Competitive pressures and strategic execution risks further exacerbate these issues. Despite decreasing expenses, the potential for constrained operational flexibility and unclear management responses in the Q&A section contribute to a negative sentiment. The lack of new partnerships or strong positive catalysts, coupled with competitive pressures in a challenging market, suggests a negative stock price movement in the short term.
Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals financial constraints with limited cash reserves and working capital, increased G&A expenses, and decreased R&D spending. While management is optimistic about product launches and partnerships, the market entry challenges, competitive pressures, and supply chain risks pose significant uncertainties. The Q&A section highlights the company's strategic focus but also underscores financial limitations and the need for careful execution. Overall, the negative financial health and strategic risks outweigh positive developments, leading to a negative sentiment rating.
Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed outlook. Positive factors include strategic partnerships, grant funding, and a strengthened balance sheet. However, financial constraints, regulatory hurdles, and market competition pose significant risks. The company's dual-path strategy and product pipeline are promising, but uncertainties in execution and economic conditions temper optimism. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
DARE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
